Imaging Biomarkers of Knee Osteoarthritis

膝骨关节炎的影像生物标志物

基本信息

批准号：
9323286
负责人：
Ravinder Regatte
金额：
$ 62.84万
依托单位：
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-08-01 至 2022-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9323286
关键词：
Affect Biochemical Biological Markers Biological Models Cartilage Chondroitin Sulfates Clinical Clinical Protocols Collagen Collagen Fiber Collagen Type II Communities Data Degenerative polyarthritis Development Disease Disease Progression Early Diagnosis Evaluation Extracellular Matrix Future Goals Healthcare Systems Human Hydration status Image Joints Knee Injuries Knee Osteoarthritis Lead Magnetic Resonance Imaging Maps Measurement Methods Monitor Morphology Multicenter Studies Musculoskeletal Organ Outcome Pain Pathologic Processes Patients Performance Pharmacologic Substance Physiologic pulse Population Proteoglycan Protocols documentation Relaxation Research Research Personnel Risk Sampling Scanning Severity of illness Site Techniques Therapeutic Agents Time Tissue Engineering Tissues Translating Treatment Efficacy Treatment Protocols United States Validation Western Ontario and McMaster Universities Arthritis Index absorption articular cartilage base cartilage degradation clinical research site cohort data space healing high risk high risk population imaging approach imaging biomarker in vivo indexing knee pain macromolecule non-invasive imaging novel personalized medicine premature prevent reconstruction repaired

项目摘要

PROJECT SUMMARY Osteoarthritis (OA) is a degenerative joint disease, affecting more than 27 million people in the United States alone. By 2030 approximately 67 million people will be affected by OA. This large affected population and the severe consequent debility of OA lead to significant expenses to the health care system. OA is characterized by biochemical, structural and morphologic degradation of components of the extracellular matrix (ECM) of articular cartilage. The ECM is composed of primarily two groups of macromolecules including proteoglycan (PG) and collagen fibers. Early diagnosis of cartilage degeneration would require the ability to non-invasively detect changes in PG concentration and collagen integrity before morphological changes occur. T1ρ and T2 relaxation times are affected by these pathological processes and are the most widely used biochemical cartilage MRI sequences worldwide. Several researchers have demonstrated that the T1ρ relaxation time is more sensitive to proteoglycan content of the cartilage, while T2 relaxation time is more sensitive to collagen orientation and integrity of network and hydration. These imaging biomarkers have potential to detect early stages of the disease (pre-clinical), quantitatively assess disease severity, monitor disease progression and possibly monitor OA therapy. The overarching goal of this proposal is to develop, evaluate and translate highly accelerated 3D-T1ρ and T2 mapping (each protocol under 5 minutes) for in-vivo knee OA applications on a standard clinical 3T scanner employing novel compressed sensing (CS) and parallel imaging (PI) strategies. The proposed accelerated 3D- T1ρ and T2 mapping techniques can be easily incorporated into routine clinical protocols for biochemical assessment of cartilage in addition to standard morphological evaluation and could serve as future imaging biomarkers for disease modifying therapies for OA. The outcome of this proposed study will significantly impact our ability for personalized treatment regimens and possibly prevent the development of premature OA. Finally, we intend on disseminating the sequences to other academic sites for widespread implementation and future multicenter studies.

项目摘要骨关节炎（OA）是一种退化性关节疾病，影响了美国超过2700万人独自的。到2030年，大约有6700万人将受到OA的影响。受影响的人口和 OA的严重耐用性导致了医疗保健系统的巨大费用。 OA是特征的通过生化，结构和形态降解的细胞外基质（ECM）的分量关节软骨。 ECM由主要的两组大分子组成，包括蛋白聚糖（PG）和胶原蛋白纤维。软骨变性的早期诊断将需要非侵入性的能力在形态变化发生之前，检测PG浓度和胶原蛋白完整性的变化。 T1ρ和T2 放松时间受这些病理过程的影响，是最广泛使用的生化软骨MRI序列全球。一些研究人员表明，T1ρ松弛时间是对软骨的蛋白聚糖含量更敏感，而T2松弛时间对胶原蛋白更敏感网络和水合的方向和完整性。这些成像生物标志物具有早期检测的潜力疾病的阶段（临床前），定量评估疾病的严重程度，监测疾病进展和可能监测OA治疗。该提案的总体目标是开发，评估和翻译高度加速的3D-T1ρ和T2 用于在标准临床3T扫描仪上的体内膝盖OA应用的映射（每个协议不到5分钟）采用新颖的压缩感应（CS）和并行成像（PI）策略。提议的加速3D- T1ρ和T2映射技术可以轻松地纳入常规临床方案中的生化临床方案除了标准形态评估外，对软骨的评估，并且可以用作将来的成像 OA修饰疗法的疾病生物标志物。这项拟议的研究的结果将显着影响我们的个性化治疗方案的能力，可能会阻止过早OA的发展。最后，我们打算将序列传播到其他学术网站以进行宽度实施和未来多中心研究。